California State Teachers Retirement System 13F: Cuts AMGN Stake by $7.2M
California State Teachers Retirement System trimmed its holdings in Amgen Inc. by 19,940 shares, reducing its stake to 825,116 shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
California State Teachers Retirement System sold 19,940 shares from its stake in Amgen Inc. ($AMGN), a 2.36% decrease, according to a 13F filing with the SEC dated May 18, 2026. It reported 825,116 shares worth $298 million at the end of the quarter.
Since the filing, $AMGN is up 3.6% after 1 week, up 5.3% after 1 month and up 34.1% to date (from the $322.51 close on May 18, 2026).
Find the original: California State Teachers Retirement System 13F filings on SEC EDGAR
AMGN
Amgen Inc.
Key Points
- California State Teachers Retirement System trimmed its stake in Amgen Inc. by 19,940 shares, bringing its total to 825,116 shares valued at approximately $298 million as of May 18, 2026.
- The stock traded at $361.17 on the day this article was published, down from a previous close of $426.11.
- Analysts maintain a consensus 'hold' rating on Amgen, with a mean price target of $394.98 from 29 analysts.
Get $AMGN trade alerts by text
We text you when insiders, Congress or big funds trade $AMGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Amgen Inc. alert may contain errors. Disclosures
CalSTRS Reduces Amgen Holdings
California State Teachers Retirement System, also known as CalSTRS, trimmed its position in Amgen Inc. (NasdaqGS: AMGN) by 19,940 shares, reducing its total holdings to 825,116 shares. This move represents a 2.36% decrease in its stake, valued at about $298 million as of May 18, 2026.
Other Funds in the Same Quarter
In this quarter, other institutional investors have made notable changes to their Amgen holdings. However, specific data from peers was not available in this filing.
How Amgen Inc. Stock Has Traded
Amgen shares were priced at $361.17 on the publication day, which is a significant drop from its previous close of $426.11. The stock has traded between a 52-week low of $288.00 and a high of $447.03, indicating some volatility in its price.
Analysts Set New Price Targets
Analysts have recently maintained their ratings on Amgen. On October 13, 2026, Guggenheim kept its rating at 'Neutral' with a price target of $378.00, down from $388.00. BMO Capital also maintained a 'Market Perform' rating with a target of $415.00, reduced from $450.00. Overall, the consensus from 29 analysts suggests a 'hold' recommendation with a mean price target of $394.98.
What Amgen Inc. Does
Amgen Inc. is a major player in the healthcare sector, focusing on developing and manufacturing human therapeutics. Its key products include treatments for various conditions such as rheumatoid arthritis, osteoporosis, and certain cancers. This recent stake reduction by CalSTRS reflects a cautious approach amid fluctuating stock performance.
What’s Next for Amgen
Looking ahead, investors will be watching for Amgen's next earnings report scheduled for November 3, 2026. As a reminder, this filing reflects holdings as of May 18, 2026, and may not represent the fund's current position. Further updates from CalSTRS and other institutional investors are expected as they adjust their portfolios.
Related Filing Alerts
Source: California State Teachers Retirement System's 13F filing on $AMGN (May 18, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: California State Teachers Retirement System 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts